305 related articles for article (PubMed ID: 20461441)
1. Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Bang YJ; Kang YK; Kang WK; Boku N; Chung HC; Chen JS; Doi T; Sun Y; Shen L; Qin S; Ng WT; Tursi JM; Lechuga MJ; Lu DR; Ruiz-Garcia A; Sobrero A
Invest New Drugs; 2011 Dec; 29(6):1449-58. PubMed ID: 20461441
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
10. Phase II open-label study of sunitinib in patients with advanced breast cancer.
Yardley DA; Dees EC; Myers SD; Li S; Healey P; Wang Z; Brickman MJ; Paolini J; Kern KA; Citrin DL
Breast Cancer Res Treat; 2012 Dec; 136(3):759-67. PubMed ID: 23073758
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Reynolds C; Spira AI; Gluck L; Bradie-Muller SJ; Zhan F; Boehm KA; Asmar L
Invest New Drugs; 2013 Oct; 31(5):1330-8. PubMed ID: 23761052
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
Propper D; Jones K; Anthoney DA; Mansoor W; Ford D; Eatock M; Agarwal R; Inatani M; Saito T; Abe M; Evans TR
BMC Cancer; 2016 Oct; 16(1):779. PubMed ID: 27724887
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
16. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Moehler M; Gepfner-Tuma I; Maderer A; Thuss-Patience PC; Ruessel J; Hegewisch-Becker S; Wilke H; Al-Batran SE; Rafiyan MR; Weißinger F; Schmoll HJ; Kullmann F; von Weikersthal LF; Siveke JT; Weusmann J; Kanzler S; Schimanski CC; Otte M; Schollenberger L; Koenig J; Galle PR
BMC Cancer; 2016 Aug; 16(1):699. PubMed ID: 27582078
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Kang YK; Yoo C; Ryoo BY; Lee JJ; Tan E; Park I; Park JH; Choi YJ; Jo J; Ryu JS; Ryu MH
Br J Cancer; 2013 Oct; 109(9):2309-15. PubMed ID: 24084771
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
20. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
